These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 20687232)
1. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. Compérat E; Rouprêt M; Drouin SJ; Camparo P; Bitker MO; Houlgatte A; Cancel-Tassin G; Cussenot O Prostate; 2010 Nov; 70(15):1622-7. PubMed ID: 20687232 [TBL] [Abstract][Full Text] [Related]
2. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457 [TBL] [Abstract][Full Text] [Related]
3. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
4. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661 [TBL] [Abstract][Full Text] [Related]
5. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068 [TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Karam JA; Lotan Y; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF Prostate; 2007 May; 67(6):614-22. PubMed ID: 17299799 [TBL] [Abstract][Full Text] [Related]
7. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy. Giesing M; Suchy B; Driesel G; Molitor D BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074 [TBL] [Abstract][Full Text] [Related]
8. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related]
9. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Kupelian P; Katcher J; Levin H; Zippe C; Klein E Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737 [TBL] [Abstract][Full Text] [Related]
10. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Miyake H; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M Urol Oncol; 2010; 28(2):145-51. PubMed ID: 18848789 [TBL] [Abstract][Full Text] [Related]
11. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC; J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735 [TBL] [Abstract][Full Text] [Related]
12. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer. Ploussard G; Salomon L; Allory Y; Terry S; Vordos D; Hoznek A; Abbou CC; Vacherot F; de la Taille A BJU Int; 2010 Jul; 106(1):86-90. PubMed ID: 19930177 [TBL] [Abstract][Full Text] [Related]
13. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy. Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491 [TBL] [Abstract][Full Text] [Related]
14. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy. Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734 [TBL] [Abstract][Full Text] [Related]
15. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy. Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921 [TBL] [Abstract][Full Text] [Related]
16. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. Yang RM; Naitoh J; Murphy M; Wang HJ; Phillipson J; deKernion JB; Loda M; Reiter RE J Urol; 1998 Mar; 159(3):941-5. PubMed ID: 9474188 [TBL] [Abstract][Full Text] [Related]
17. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence. Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456 [TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255 [TBL] [Abstract][Full Text] [Related]
19. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328 [TBL] [Abstract][Full Text] [Related]
20. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]